169 related articles for article (PubMed ID: 32973362)
1. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy.
Pruller J; Hofer I; Ganassi M; Heher P; Ma MT; Zammit PS
Cancer Gene Ther; 2021 May; 28(5):427-441. PubMed ID: 32973362
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3β represses MYOGENIN function in alveolar rhabdomyosarcoma.
Dionyssiou MG; Ehyai S; Avrutin E; Connor MK; McDermott JC
Cell Death Dis; 2014 Feb; 5(2):e1094. PubMed ID: 24577092
[TBL] [Abstract][Full Text] [Related]
3. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
4. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.
Calhabeu F; Hayashi S; Morgan JE; Relaix F; Zammit PS
Oncogene; 2013 Jan; 32(5):651-62. PubMed ID: 22710712
[TBL] [Abstract][Full Text] [Related]
5. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.
Azatian A; Yu H; Dai W; Schneiders FI; Botelho NK; Lord RV
J Gastrointest Surg; 2009 Jun; 13(6):1044-51. PubMed ID: 19277794
[TBL] [Abstract][Full Text] [Related]
7. Suicide gene therapy of rhabdomyosarcoma.
Konieczny P; Sułkowski M; Badyra B; Kijowski J; Majka M
Int J Oncol; 2017 Feb; 50(2):597-605. PubMed ID: 28035376
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
9. PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis.
Marshall AD; Picchione F; Geltink RI; Grosveld GC
Neoplasia; 2013 Jul; 15(7):738-48. PubMed ID: 23814486
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.
Lee MH; Jothi M; Gudkov AV; Mal AK
Cancer Res; 2011 Jun; 71(11):3921-31. PubMed ID: 21493592
[TBL] [Abstract][Full Text] [Related]
11. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
Bois PR; Izeradjene K; Houghton PJ; Cleveland JL; Houghton JA; Grosveld GC
J Cell Biol; 2005 Sep; 170(6):903-12. PubMed ID: 16157701
[TBL] [Abstract][Full Text] [Related]
12. SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.
Skrzypek K; Kusienicka A; Trzyna E; Szewczyk B; Ulman A; Konieczny P; Adamus T; Badyra B; Kortylewski M; Majka M
Cell Death Dis; 2018 May; 9(6):643. PubMed ID: 29844345
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
Wang ZX; Bian HB; Yang JS; De W; Ji XH
Cancer Biol Ther; 2009 Aug; 8(15):1480-8. PubMed ID: 19571664
[TBL] [Abstract][Full Text] [Related]
14. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.
Brown RE; Buryanek J; Katz AM; Paz K; Wolff JE
Oncotarget; 2016 Jul; 7(29):46263-46272. PubMed ID: 27323832
[TBL] [Abstract][Full Text] [Related]
15. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
16. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
17. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
[TBL] [Abstract][Full Text] [Related]
18. IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).
Picchione F; Pritchard C; Lagutina I; Janke L; Grosveld GC
Carcinogenesis; 2011 Apr; 32(4):452-61. PubMed ID: 21177767
[TBL] [Abstract][Full Text] [Related]
19. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.
Xia SJ; Holder DD; Pawel BR; Zhang C; Barr FG
Am J Pathol; 2009 Dec; 175(6):2600-8. PubMed ID: 19893043
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
Hu Q; Yuan Y; Wang C
PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
